<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________________ to __________________
Commission file number 1-10538
GAMMA BIOLOGICALS, INC.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
Texas 74-1668436
- ------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
3700 Mangum Road, Houston, Texas 77092
---------------------------------------------------
(Address of principal executive offices) (Zip code)
(713) 681-8481
---------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
At November 13, 1996: 4,602,802 shares
<PAGE>
PART I. FINANCIAL INFORMATION
GAMMA BIOLOGICALS, INC.
Consolidated Balance Sheets
<TABLE>
<CAPTION>
SEPTEMBER 30, 1996 MARCH 31, 1996
------------------ --------------
(UNAUDITED)
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents .................................... $ 3,696,069 $ 3,724,379
Short-term investments ....................................... 100,000 100,000
Receivables - net of allowance for doubtful ..................
accounts of $175,384 and $156,839, respectively ............ 3,236,310 3,696,880
Inventories .................................................. 3,714,517 3,240,360
Prepaid expenses ............................................. 376,963 369,380
Deferred taxes ............................................... 121,300 110,900
--------------- ---------------
Total current assets ......................................... 11,245,159 11,241,899
PROPERTY - at cost, net of accumulated --------------- ---------------
depreciation and amortization of $5,823,978
and $5,684,907, respectively ................................. 5,746,347 5,178,063
CASH VALUE OF LIFE INSURANCE ................................... 1,859,665 1,729,774
EXCESS OF COST OVER NET ASSETS ACQUIRED-NET .................... 139,397
OTHER ASSETS ................................................... 250,684 275,964
--------------- ---------------
TOTAL ........................................................ $ 19,241,252 $ 18,425,700
=============== ===============
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current portion of long-term obligations...................... $ 115,314 $ 96,588
Accounts payable - trade ..................................... 643,888 487,681
Dividends payable ............................................ 115,071 113,796
Accrued salaries and other expenses .......................... 278,781 244,852
--------------- ---------------
Total current liabilities .................................... 1,153,054 942,917
--------------- ---------------
LONG-TERM OBLIGATIONS .......................................... 410,943 353,097
--------------- ---------------
DEFERRED TAXES ................................................. 336,002 277,600
--------------- ---------------
SHAREHOLDERS' EQUITY ........................................... 17,341,253 16,852,086
--------------- ---------------
TOTAL ........................................................ $ 19,241,252 $ 18,425,700
=============== ===============
</TABLE>
See notes to unaudited consolidated financial statements.
2
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Income
(Unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------- -------------
1996 1995 1996 1995
------------ ------------ ------------ -------------
<S> <C> <C> <C> <C>
NET SALES ........................................... $ 4,176,869 $ 4,331,561 $ 8,388,905 $ 8,419,798
COST OF SALES ....................................... 1,731,526 1,920,354 3,716,118 3,837,027
------------ ------------ ------------ ------------
GROSS MARGIN ........................................ 2,445,343 2,411,207 4,672,787 4,582,771
------------ ------------ ------------ ------------
OPERATING EXPENSES:
Selling ........................................... 888,145 871,105 1,751,511 1,729,696
General and administrative ........................ 552,063 585,949 1,085,292 1,133,465
Shipping and warehouse ............................ 184,186 243,968 353,004 472,482
Research and development .......................... 365,734 328,715 695,650 628,957
------------ ------------ ------------ ------------
Total operating expense ......................... 1,990,128 2,029,737 3,885,457 3,964,600
------------ ------------ ------------ ------------
OPERATING INCOME .................................... 455,215 381,470 787,330 618,171
------------ ------------ ------------ ------------
OTHER INCOME (EXPENSE):
Interest income ................................... 53,788 67,931 101,594 136,875
Interest expense .................................. (10,700) (17,661) (22,112) (32,050)
Other - net ....................................... 3,417 (1,456) (562) 22,279
------------ ------------ ------------ ------------
Other income - net .............................. 46,505 48,814 78,920 127,104
------------ ------------ ------------ ------------
INCOME BEFORE INCOME TAXES .......................... 501,720 430,284 866,250 745,275
INCOME TAXES ........................................ 169,400 126,700 313,500 221,200
------------ ------------ ------------ ------------
NET INCOME .......................................... $ 332,320 $ 303,584 $ 552,750 $ 524,075
============ ============ ============ ============
Weighted average number of common
and common equivalent shares outstanding ........... 4,574,656 4,597,956 4,574,058 4,597,511
------------ ------------ ------------ ------------
Net income per common and common
equivalent share ................................... $ .07 $ .07 $ .12 $ .11
=========== ============ ============ ============
</TABLE>
See notes to unaudited consolidated financial statements.
3
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Changes in Shareholders' Equity
(Unaudited)
<TABLE>
<CAPTION>
SIX MONTHS ENDED
SEPTEMBER 30,
-------------
1996 1995
----- ----
SHARES AMOUNT SHARES AMOUNT
------ ------- ------ -------
<S> <C> <C> <C> <C>
COMMON STOCK
Balance, beginning of period ............... 4,711,365 $ 471,136 4,700,303 $ 470,030
Acquisition of wholly-owned subsidiary ..... 50,000 5,000
Exercise of stock options .................. 1,000 100 3,000 300
--------- ---------- --------- ----------
Balance, end of period 4,762,365 476,236 4,703,303 470,330
--------- ---------- --------- ----------
CAPITAL IN EXCESS OF PAR
Balance, beginning of period ............... 13,512,836 13,482,615
Acquisition of wholly-owned subsidiary ..... 157,500
Exercise of stock options .................. 2,710 8,130
---------- ----------
Balance, end of period ..................... 13,673,046 13,490,745
---------- ----------
RETAINED EARNINGS
Balance, beginning of period ............... 3,988,022 3,619,289
Net income ................................. 552,750 524,075
Dividends declared ......................... (228,893) (227,171)
---------- ----------
Balance, end of period ..................... 4,311,879 3,916,193
---------- ----------
TREASURY STOCK ............................... (159,563) (1,119,908) (159,169) (1,118,258)
--------- ---------- --------- ----------
TOTAL SHAREHOLDERS' EQUITY ................... 4,602,802 $17,341,253 4,544,134 $16,759,010
========= ========== ========= ==========
</TABLE>
See notes to unaudited consolidated financial statements.
4
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Cash Flows
(Unaudited)
SIX MONTHS ENDED
SEPTEMBER 30,
-------------
1996 1995
---- ----
[INCREASE (DECREASE) IN CASH]
Cash flows from operating activities:
Cash received from customers .............. $ 9,048,041 $ 8,975,066
Interest received ......................... 103,792 74,517
Cash paid to suppliers and employees ...... (7,754,624) (7,849,923)
Interest paid ............................. (22,112) (32,050)
Income taxes paid ......................... (243,000) (200,000)
------------ ------------
Net cash provided by operating activities . 1,132,097 967,610
------------ ------------
Cash flows from investing activities:
Property additions ........................ (895,738) (965,075)
Increase in cash value of life insurance .. (129,891) (95,867)
Purchase of investments ................... (955,449)
Proceeds from investments ................. 2,343 1,030,868
Investment in subsidiary .................. 142,659
Proceeds from sale of equipment ........... 49 8,595
------------ ------------
Net cash used in investing activities ..... (880,578) (976,928)
------------ ------------
Cash flows from financing activities:
Payments on long-term obligations ......... (55,022) (108,873)
Exercise of stock options ................. 2,811 8,430
Dividends paid ............................ (227,618) (227,133)
------------ ------------
Net cash used in financing activities ..... (279,829) (327,576)
------------ ------------
Net decrease in cash ........................ (28,310) (336,894)
Cash and cash equivalents at beginning
of pereiod ................................ 3,724,379 1,795,854
------------ ------------
Cash and cash equivalents at end of period .. $ 3,696,069 $ 1,458,960
============ ============
5
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Cash Flows
(Unaudited)
Reconciliation of Net Income to
Net Cash Provided by Operating Activities
SIX MONTHS ENDED
SEPTEMBER 30,
-------------
1996 1995
---- ----
Net Income $ 552,750 $ 524,075
Adjustments to reconcile net income to
cash provided by operating activities:
Depreciation ............................. 359,717 319,013
Loss on sale of fixed assets ............. 2,863 102
Decrease in accounts receivable .......... 608,359 584,768
(Gain) loss on sale of investments ....... 2,198 (93,226)
Increase in inventory .................... (548,645) (290,227)
Decrease in prepaid expenses ............. (7,583) 76,361
Decrease in other assets ................. 25,281 36,839
Increase (decrease) in accounts payable .. 160,934 (147,739)
Decrease in accrued salaries and other
expenses ................................ (23,777) (42,356)
---------- ----------
Net Cash Provided by
Operating Activities ....................... $1,132,097 $ 967,610
========== ==========
Supplemental Schedule of Non-Cash Investing and Financing Activities:
In March 1996, the company outsourced the assembly of plastic droppers and
SegmentSamplers (TM). As a result, inventory of component parts totaling
$282,886 was transferred to outside vendors and a corresponding receivable due
from the vendors was recorded. This receivable is being reduced as assembled
parts are delivered, with the cost of components deducted from the vendors'
selling price. During the six months ended September 30, 1996 additional
inventory valued at $101,000 was transferred to outside vendors and the
outstanding receivable balance at September 30, 1996 was $110,424.
The company purchased 100% of the outstanding shares of Gamma Biologicals, B.V.
effective September 30, 1996, for 50,000 shares of common stock. In conjunction
with the acquisition, assets of $336,000 (including $143,000 cash) were received
and liabilities of $313,000 were assumed.
See notes to unaudited consolidated financial statements.
6
<PAGE>
GAMMA BIOLOGICALS, INC.
Notes to Consolidated Financial Statements
(Unaudited)
1. Reconciliation of statutory rate with effective United States income tax
rate:
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
------------- -------------
1996 1995 1996 1995
------ ------ ------ ------
<S> <C> <C> <C> <C>
Statutory rate .................................................... 34.0% 34.0% 34.0% 34.0%
Increase (decrease) resulting from:
Exempt export earnings ......................................... (2.3) (3.8) (2.7) (4.4)
Life insurance premiums ........................................ .5 .8 .6 .9
Valuation of temporary differences ............................. .9 (2.2) 3.5 (1.5)
Other-net ...................................................... .7 .7 .8 .8
------ ------ ------ ------
Effective tax rate ............................................... 33.8% 29.5% 36.2% 29.8%
====== ====== ====== ======
</TABLE>
The provision for deferred income taxes is based on the liability method
prescribed by SFAS No. 109. A deferred income tax liability or asset is
recognized for temporary differences between the tax basis of assets and
liabilities and their reported amounts in the financial statements that will
result in net taxable or deductible amounts in future years. Significant
components of the company's deferred tax assets (liabilities) are as follows:
<TABLE>
<CAPTION>
SEPTEMBER 30, 1996 MARCH 31, 1996
------------------ --------------
<S> <C> <C>
Allowance for bad debts .......................................... $ 59,600 $ 53,300
Inventory costs capitalized ...................................... 61,700 57,600
----------- ----------
Net current deferred tax asset ................................. 121,300 110,900
----------- ----------
Difference between book and tax basis of
property, plant and equipment .................................. (310,400) (253,000)
Other ............................................................ (25,602) (24,600)
----------- ----------
Net noncurrent deferred tax liability .......................... (336,002) (277,600)
----------- ----------
Net deferred tax liability ....................................... $ (214,702) $ (166,700)
=========== ==========
</TABLE>
2. Net income per common and common equivalent share is computed using weighted
average number of shares and dilutive equivalent shares outstanding during
each period. The weighted average number of shares for the three month period
ended September 30, was 4,574,656 in 1996 and 4,597,956 in 1995; for the six
month period then ended, 4,574,058 in 1996 and 4,597,511 in 1995.
7
<PAGE>
3. Inventories are valued at the lower of cost or market value, based on the
cost method summarized below:
SEPTEMBER 30, 1996 MARCH 31, 1996
------------------ --------------
First-in, first out:
Finished products ............. $ 1,837,131 $ 1,387,826
Products in process ........... 406,791 499,579
------------ ------------
2,243,922 1,887,405
------------ ------------
Specific identification:
Raw material .................. 760,314 737,717
------------ ------------
760,314 737,717
------------ ------------
Average:
Supplies ...................... 710,281 615,238
------------ ------------
Total ........................ $ 3,714,517 $ 3,240,360
============ ============
4. INVESTMENTS
In accordance with SFAS No. 115, "Accounting for Certain Investments in Debt
and Equity Securities", the company classified its investments in debt
securities as "held to maturity", since the company has the positive intent
and ability to hold its investments in debt securities to maturity. These
investments are reported at amortized cost. Investments in debt securities
are summarized as follows:
<TABLE>
<CAPTION>
UNREALIZED CARRYING
TYPE CLASSIFICATION FAIR VALUE GAIN (LOSS) VALUE
----- -------------- ---------- ----------- ---------
<S> <C> <C> <C> <C>
Six months ended September 30, 1996
Debt securities:
Certificates of Deposit - due 3/10/97 Held to maturity $ 100,000 $ 100,000
----------------------------------------------
Total debt securities 100,000 100,000
----------------------------------------------
Total investments $ 100,000 $ 100,000
==============================================
Six months ended September 30, 1995
Debt securities:
U.S. Government:
Federal Natl Mtg Assn - due 11/29/95 Held to maturity $ 990,400 $ 4,083 $ 986,317
Treasury Notes - due 3/31/96 Held to maturity 997,500 854 996,646
Certificates of Deposit - due 3/11/96 Held to maturity 100,000 100,000
----------------------------------------------
Total debt securities 2,087,900 4,937 2,082,963
----------------------------------------------
Total investments $ 2,087,900 $ 4,937 $ 2,082,963
==============================================
</TABLE>
8
<PAGE>
5. In the opinion of management, the unaudited consolidated condensed financial
statements for Gamma Biologicals, Inc. (the "company") include all
adjustments (consisting solely of normal recurring adjustments) necessary for
a fair presentation of the financial position of the company as of September
30, 1996, the results of operations of the three and six month periods ended
September 30, 1996 and 1995 and cash flows for the six month periods ended
September 30, 1996 and 1995. Although management believes the disclosures in
these financial statements are adequate to make the information presented not
misleading, certain information and footnote disclosures normally included in
annual financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted pursuant to the rules
and regulations of the Securities and Exchange Commission. The results of
operations for the period ended September 30, 1996 are not necessarily
indicative of the results to be expected for the full year.
6. LONG-TERM OBLIGATIONS
Long-term obligations consist of:
<TABLE>
<CAPTION>
SEPTEMBER 30, 1996 MARCH 31, 1996
------------------ --------------
<S> <C> <C>
Mortgage note, due monthly through 2000 $ 391,865 $ 430,422
Note payable-foreign, due semiannually
through 2000 131,594
Other obligations 2,798 19,263
------------- ----------
526,257 449,685
Less current portion 115,314 96,588
------------- ----------
Total long-term obligations $ 410,943 $ 353,097
============= ==========
</TABLE>
The mortgage note bears interest at the bank's base rate, but not less than 7%
nor more than 13%. At September 30, 1996, the note bore interest at 9.25%. The
mortgage note is collaterized by a first lien on the company's land and
building. The foreign note payable bears interest at 7%.
7. SALES BY GEOGRAPHIC AREA
The company operates within one dominant segment - the manufacture and sale
of blood bank and diagnostic products - and has no customer which accounts
for 10% or more of its total sales. During the three and six month periods
ended September 30, 1996 and 1995, the company operated in one geographic
area, the United States, from which it sold to numerous countries. Subsequent
to the September 30, 1996 acquisition of Gamma Biologicals, B.V., the company
will operate in two geographic areas, the United States and Europe.
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
-------------------------------- ----------------------------------
1996 1995 1996 1995
---- ---- ---- ----
<S> <C> <C> <C> <C>
Net sales to unaffiliated customers:
United States $2,841,918 $3,146,710 $5,919,396 $6,137,258
Europe 368,436 383,644 757,591 771,468
Pacific Region 390,967 326,714 708,208 607,810
Mexico, Central and South America 401,917 247,795 642,406 406,744
Middle East 123,768 159,615 265,975 368,186
Other 49,863 67,083 95,329 128,332
---------- ---------- ---------- -----------
Total $4,176,869 $4,331,561 $8,388,905 $8,419,798
========== ========== ========== ===========
</TABLE>
9
<PAGE>
8. ACQUISITION OF WHOLLY-OWNED SUBSIDIARY
Effective September 30, 1996, the company acquired 100% of the outstanding
shares of its distributor in the Netherlands, Gamma Biologicals, B.V.
Consideration for the acquisition was 50,000 shares of Gamma common stock,
valued at $3.25 per share, the market price on the effective date. The
acquisition has been accounted for using the purchase method of accounting,
and accordingly, the purchase price has been allocated to the assets
purchased and the liabilities assumed based upon the fair values at the date
of acquisition. The excess of the purchase price over the fair values of the
net assets acquired was $139,397 and has been recorded as goodwill, which
will be amortized over five years.
On the basis of a pro forma consolidation of the results of operations as if
the acquisition had taken place at April 1, 1995 rather than at September
30, 1996, consolidated net sales for the six month periods ending September
30, 1996 and 1995 would have been approximately $8,740,000 and $8,710,000.
Consolidated income and earnings per share would have been $596,000 and $.13
for 1996 and $558,000 and $.12 for 1995. Such pro forma amounts are not
necessarily indicative of what the actual consolidated results of operations
might have been if the acquisition had been effective at April 1, 1995.
Gamma Biologicals, B.V. was formed in November 1993 to market Gamma products
and certain noncompeting product lines in the Netherlands. Subsequent to the
acquisition, the subsidiary will continue to sell directly in the Benelux
area, as well as serve as a European distribution center and manufacturing
site for the ReACT test system.
10
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
- ---------------------
THREE MONTHS ENDED SEPTEMBER 30, 1996
- -------------------------------------
Revenues decreased 3.6% for the three months ended September 30, 1996 compared
with the same period in 1995. Domestic sales fell 9.6% due primarily to the
shortage of human-source raw material for certain rare reagents and the
backorder of one third-party product. Our supplier introduced an improved
version of this product late in the second quarter; this should eliminate the
supply shortages and FDA recalls experienced over the past twelve months.
Internationally, with exclusive distributorships established in every country in
Central and South America, sales continue to strengthen in this region,
increasing 62% compared to the same period last year. Export sales rose 13%
overall in the current period.
Gross margin as a percentage of sales rose to 58.5% in the current period due
to the conversion of source material for additional high-volume products to
clone-based raw materials grown in our in-house clone lab. This conversion
continues to improve manufacturing efficiencies in both reagent manufacturing
and the clone lab as more products are converted.
Selling and general and administrative expenses remained relatively constant
with the prior period. Shipping and warehouse expenses fell 25% compared with
the same period in 1995. Relocation of the shipping department to new
facilities that fully utilize the bar coding system implemented last year has
significantly improved accuracy and control. Future periods should experience
further efficiencies due to the completion in September of a computer software
upgrade that further streamlined the order fulfillment process.
Research and development expenses increased 11% in 1996 after a 27% increase
in 1995, due to costs associated with ReACT alpha testing and Olympus reagent
field studies.
Interest income declined due to a reduction in the amount of funds invested
and a change in the investment mix in the current period. Interest expense
decreased due to normal debt retirement.
The provision for income taxes rose 34% due to higher taxable income in the
current period.
In March 1995, the Financial Accounting Standards Board("FASB") issued SFAS
No. 121, "Accounting for the Impairment of Long-Lived Assets to be Disposed Of",
which sets forth guidance as to when to recognize an impairment of long-lived
assets, including goodwill, and how to measure such an impairment. The company
adopted SFAS No. 121 on April 1, 1996. The adoption of SFAS No. 121 did not
have a material effect on the company's results of operations or financial
position.
In October 1995, the FASB issued SFAS No. 123, "Accounting for Stock-Based
Compensation", which permits, but does not require, a fair-value-based method
for accounting for employee stock option plans which results in compensation
expense being recognized in the results of operations when stock options are
granted. The company adopted SFAS No. 123 on April 1, 1996. We plan to
continue the use of our current intrinsic-value-based method of accounting for
such plans where no compensation expense is recognized. However, as required by
SFAS No. 123, we will provide pro forma disclosure of net income and earnings
per share, if significantly different from reported amounts, in the notes to the
annual financial statements as if the fair-value-based method had been applied.
The company has not granted any stock-based compensation instruments in the
three and six month periods ended September 30, 1996.
11
<PAGE>
SIX MONTHS ENDED SEPTEMBER 30, 1996
- -----------------------------------
Net income for the six months ended September 30, 1996 rose 5.5% over the
prior period. A 2% increase in gross margin on relatively flat revenues coupled
with a 2% reduction in operating expenses as outlined above for the three month
period ended September 30, 1996 has resulted in a 16% increase in pretax
earnings to date which was partially offset by a 42% increase in income taxes.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
Net cash flows increased approximately $309,000 during the six month period
ended September 30, 1996 compared with the same period in 1995. Operating cash
flows improved by nearly $164,000, due primarily to the reduction of the
receivable resulting from outsourcing the assembly of plastic droppers and
SegmentSamplers. Management believes that operating cash flows will be
sufficient to meet future operating needs.
With the completion of improvements to the shipping area in May 1996 and the
computer system upgrade implementation in September 1996, capital expenditures
have begun to slow, decreasing $70,000 from the same period last year. Further
domestic expenditures are planned during the last half of fiscal 1997 to
streamline the packaging function and add capacity to the monoclonal laboratory.
Cash from investing activities also improved by $143,000 due to the acquisition
of 100% of the outstanding shares of its distributor in the Netherlands (see
Note 8).
The new subsidiary, Gamma Biologicals, B.V. will move its operations to a
larger facility in the Amsterdam area in the third quarter. The additional
square footage will allow the subsidiary to begin European distribution
activities and ReACT manufacturing during the fourth quarter of fiscal 1997. We
expect that capital expenditures for leasehold improvements and equipment will
not exceed $100,000 during the next six months.
The company recently requested proposals from several medical equipment
manufacturers for the development of a completely automated version of the ReACT
system. Although the cost to develop such a system cannot yet be estimated, the
development process will take at least 12 months. We submitted a 510K
application to the FDA in October 1996 for approval to market a semi-automated
ReACT system, and expect to begin selling this system internationally before
fiscal year-end.
The company's existing capital resources, consisting of $3,800,000 in cash and
short-term investments and a $1,500,000 revolving credit line, should be
sufficient to support planned product development and capital improvements
during the next 12 months.
12
<PAGE>
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits, Part II
(27) Article 5 Financial Data Schedule
(b) Reports on Form 8-K - None
13
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.
GAMMA BIOLOGICALS, INC.
November 13, 1996 By: /s/ David E. Hatcher
---------------------
David E. Hatcher
President
(Chief Executive Officer)
November 13, 1996 By: /s/ Margaret J. O'Bannion
--------------------------
Margaret J. O'Bannion
Vice President - Finance
(Chief Financial Officer)
14
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
BALANCE SHEETS AND STATEMENTS OF CONSOLIDATED INCOME AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> MAR-31-1997
<PERIOD-END> SEP-30-1996
<CASH> 3,696,069
<SECURITIES> 100,000
<RECEIVABLES> 3,411,694
<ALLOWANCES> 175,384
<INVENTORY> 3,714,517
<CURRENT-ASSETS> 11,245,159
<PP&E> 11,570,325
<DEPRECIATION> 5,823,978
<TOTAL-ASSETS> 19,241,252
<CURRENT-LIABILITIES> 1,153,054
<BONDS> 410,943
0
0
<COMMON> 476,236
<OTHER-SE> 16,865,017
<TOTAL-LIABILITY-AND-EQUITY> 19,241,252
<SALES> 8,388,905
<TOTAL-REVENUES> 8,388,905
<CGS> 3,716,118
<TOTAL-COSTS> 2,800,165
<OTHER-EXPENSES> 1,055,904
<LOSS-PROVISION> 29,388
<INTEREST-EXPENSE> 22,112
<INCOME-PRETAX> 866,250
<INCOME-TAX> 313,500
<INCOME-CONTINUING> 552,750
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 552,750
<EPS-PRIMARY> .12
<EPS-DILUTED> .12
</TABLE>
